19.3 C
New York
Tuesday, June 9, 2026

Tag: convertible

newssourceFORcompanyinformationcontent1marketreleases

EdgeMode Signs Non-Binding Term Sheet for $4 Million Convertible Note to Support Infrastructure Development and Growth Strategy

EdgeMode Signs Non-Binding Term Sheet for $4 Million Convertible Note to Support Infrastructure Development and Growth Strategy

ALLIED GOLD REPORTS SECOND QUARTER 2025 RESULTS: SOLID PRODUCTION AND PROGRESS ON GROWTH PIPELINE

TORONTO, Aug. 6, 2025 /CNW/ - Allied Gold Corporation (TSX: AAUC) (NYSE: AAUC) ("Allied" or the "Company") reports second quarter of 2025 production of...

ALLIED GOLD REPORTS SECOND QUARTER 2025 RESULTS: SOLID PRODUCTION AND PROGRESS ON GROWTH PIPELINE

TORONTO, Aug. 6, 2025 /PRNewswire/ - Allied Gold Corporation (TSX: AAUC) (NYSE: AAUC) ("Allied" or the "Company") reports second quarter of 2025 production of...

Diversified Royalty Corp. Announces Second Quarter 2025 Results and Strongest Adjusted Revenue(1) Quarter in its History

VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV and DIV.DB.A) (the “Corporation” or “DIV”) is pleased to announce its financial results for three months ended June 30, 2025 (“Q2 2025”) and six months ended June 30, 2025.

Advantage Announces Second Quarter 2025 Financial and Operating Results

(TSX: AAV) CALGARY, AB, Aug. 6, 2025 /CNW/ - Advantage Energy Ltd. ("Advantage" or the "Corporation") is pleased to report 2025 second quarter financial and...

GOLD ROYALTY REPORTS SECOND QUARTER RESULTS; ACHIEVES RECORD REVENUE AND ADJUSTED EBITDA

VANCOUVER, BC, Aug. 6, 2025 /CNW/ - Gold Royalty Corp. ("Gold Royalty" or the "Company") (NYSE American: GROY) is pleased to announce the filing...

GOLD ROYALTY REPORTS SECOND QUARTER RESULTS; ACHIEVES RECORD REVENUE AND ADJUSTED EBITDA

VANCOUVER, BC, Aug. 6, 2025 /PRNewswire/ - Gold Royalty Corp. ("Gold Royalty" or the "Company") (NYSE American: GROY) is pleased to announce the filing...

FREEMAN CLOSES STRATEGIC PRIVATE PLACEMENT

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Aug. 6, 2025 /CNW/ - Freeman Gold Corp....

NextGen Digital Platforms Inc. to Present at the OTCQB Venture Virtual Investor Conference August 7th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy

Cosmos Health secures financing of up to $300 million to develop an ETH-backed treasury, with remaining proceeds for growth and general working capital

STAR DIAMOND CORPORATION ANNOUNCES CLOSING OF PRIVATE PLACEMENT WITH SPIRIT RESOURCES s.a.r.l.

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES/ TSX: DIAM SASKATOON, SK, Aug. 6, 2025 /CNW/ - Star Diamond Corporation (the "Company") (TSX: DIAM) is pleased to announce...

Parsons Reports Strong Second Quarter 2025 Results

Q2 2025 Financial Highlights

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).

Cryoport Reports Second Quarter 2025 Financial Results

Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 millionLife Sciences Services revenue rose...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsConvertible

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers